Comparison of allergen immunotherapy practice patterns in inhalant allergies in the United States of America and Europe: Similarities and differences 2023.

"Declaration of competing interest O Pfaar reports grants and/or personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis S.A., Mobile Chamber Experts, Indoor Biotechnologies, GlaxoSmithKline, 10.13039/501100004948Astellas Pharma Global, EUFOREA, ROXALL Medizin, 10.13039/100004336Novartis, Sanofi-Aventis and Sanofi-10.13039/100004329Genzyme, Med Update Europe GmbH, streamedup! GmbH, Pohl-Boskamp, Inmunotek S.L., John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, Wort&Bild Verlag, Verlag ME, Procter&Gamble, Alfried-Krupp Krankenhaus, Essen, all outside the submitted work; he is member of EAACI Excom, member of ext. board of directors DGAKI and coordinator, main- or co-author of different position papers and guidelines in Rhinology, Allergology and allergen-immunotherapy. S Becker reports grants and/or personal fees from ALK-Abelló, 10.13039/100009946Allergopharma, HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, MYLAN, Viatris, 10.13039/100004336Novartis, Sanofi-Aventis and Sanofi-10.13039/100004329Genzyme, 10.13039/100008894Stryker, Smart Reporting, 10.13039/100004325AstraZeneca. C Calabria has no conflicts of interest D Hartenstein declares no conflict of interest in relation to this work. Disclaimer: The views expressed in this review are the personal views of the author and may not be understood or quoted as being made on behalf of or reflecting the position of the respective national competent authorities, the European Directorate for the Quality of Medicines and HealthCare, the European Medicines Agency or one of its committees or working parties. J Jung reports no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. J Zimmer reports grants from European Directorate for the Quality of Medicines and HealthCare (EDQM), outside the submitted work. She is secretary of the WHO/IUIS Allergen Standardization Subcommittee. Disclaimer: The views expressed in this review are the personal views of the author and may not be understood or quoted as being made on behalf of or reflecting the position of the respective national competent authorities, the European Directorate for the Quality of Medicines and HealthCare, the European Medicines Agency or one of its committees or working parties. P Ponda report grants from 10.13039/100016185Aimmune, ALK-Abello, Allakos, 10.13039/501100011831DBV, 10.13039/100004336Novartis, Revolo, 10.13039/100009857Regeneron, and Siolta."

"Funding Not applicable."